Exagen (XGN) EBIT Margin (2018 - 2025)
Exagen's EBIT Margin history spans 8 years, with the latest figure at 29.91% for Q4 2025.
- For Q4 2025, EBIT Margin fell 514.0% year-over-year to 29.91%; the TTM value through Dec 2025 reached 21.13%, up 337.0%, while the annual FY2025 figure was 21.13%, 337.0% up from the prior year.
- EBIT Margin reached 29.91% in Q4 2025 per XGN's latest filing, down from 17.98% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 15.29% in Q2 2025 to a low of 184.91% in Q2 2022.
- Average EBIT Margin over 5 years is 50.37%, with a median of 37.59% recorded in 2023.
- Peak YoY movement for EBIT Margin: tumbled -13995bps in 2022, then skyrocketed 15014bps in 2023.
- A 5-year view of EBIT Margin shows it stood at 49.29% in 2021, then plummeted by -129bps to 112.88% in 2022, then skyrocketed by 67bps to 37.39% in 2023, then soared by 34bps to 24.77% in 2024, then fell by -21bps to 29.91% in 2025.
- Per Business Quant, the three most recent readings for XGN's EBIT Margin are 29.91% (Q4 2025), 17.98% (Q3 2025), and 15.29% (Q2 2025).